Peptide research · Updated October 12, 2026
Compare what each peptide has shown in studies, what approval covers, and what is still unknown.
Compare research findings and limits. This does not rank peptides or recommend treatment.
Each question shows both records together.
| Question checked | Retatrutide | Tirzepatide |
|---|---|---|
| Approval statusIs there a reviewed product for a specific use? | Retatrutide Still being studied in the United States; no FDA-approved retatrutide product | Tirzepatide Mounjaro and Zepbound have different FDA-approved uses |
| Health benefitsDid people's health improve? | RetatrutideModerate A full phase 2 report and several early phase 3 sponsor reports show meaningful results in people. Full reports for the phase 3 studies and FDA review are not complete. | TirzepatideStrong Large studies support blood-sugar and weight findings in the groups studied. FDA separately approved a heart-risk use for Mounjaro in certain adults. |
| Body changes in peopleWhat body changes did studies in people measure? | RetatrutideModerate Human dose-response and adverse-event data exist, but the development program is not complete. | TirzepatideStrong Studies have described how approved products enter and affect the body in detail. |
| Known risksWhat do we know about risks in people? | RetatrutideLimited Phase 2 exposure cannot define the full safety profile, rare risks, or long-term benefit-risk balance. | TirzepatideStrong Product labels list major warnings, including boxed warnings. They also explain when the medicine must not be used, precautions, and harmful reactions. |
| Exact productDo we know what the product contains and how well it was made? | RetatrutideLimited High for controlled clinical-trial material; low for products sold outside those trials. | TirzepatideStrong The product is well documented when it is a genuine approved medicine. This does not apply to every compounded or counterfeit (fake) version. |
Health results; use not approved
Studies measured health results in people. The substance is still being studied and is not approved for that use. Important questions remain.
Still being studied. Late-stage study reports show meaningful results in people, but no product is approved and no regulatory review is complete.
Approval statusStill being studied in the United States; no FDA-approved retatrutide product
Health results for approved uses
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. Each approved product has its own uses and safety information. An approval for one product does not automatically apply to the other.
Approval statusMounjaro and Zepbound have different FDA-approved uses
Before you compare
Use these questions to compare the research.
Which peptide has an approved product for a defined use?
What did studies in people actually measure?
Do the results apply to the same product, people, and time period?
What does this comparison still not tell you about safety or personal use?
Start with two peptides
Each page starts with the main answer, then shows what the research supports and where it stops.
Tirzepatide has approved products with current FDA labels for defined uses. Retatrutide remains investigational with meaningful but incomplete human outcome evidence. This is a regulatory and evidence-stage difference, not a potency ranking.
Evidence levels: Emerging vs EstablishedNeither BPC-157 nor TB-500 has established human healing outcomes in the reviewed records. BPC-157 has preclinical research, early human work, and registered research. TB-500 has an unresolved identity question and no adequate human outcome evidence. Both are prohibited in tested sport.
Evidence levels: Emerging vs InsufficientTesamorelin has two FDA-approved products, Egrifta SV and Egrifta WR, for one use: less belly fat in adults with HIV and lipodystrophy. Sermorelin has no current FDA-approved U.S. product, and the former Geref products are no longer sold. Studies do not show that either one slows aging or builds muscle.
Evidence levels: Established vs EmergingBoth can trigger growth-hormone release in people, through different body signals. This review found no current FDA-approved product for either in the United States. Sermorelin was once approved as Geref. Ipamorelin's phase 2 trial after bowel surgery did not show a benefit on its main outcomes. Studies do not show that either one builds muscle or slows aging.
Evidence levels: Emerging vs EmergingSemax and Selank are different seven-amino-acid peptides. Neither has an FDA-approved product in the United States. Semax is registered in Russia as nose drops. Small human studies do not show that either one improves focus or memory, and Selank is not a proven anxiety treatment.
Evidence levels: Emerging vs EmergingTesamorelin has two FDA-approved products, Egrifta SV and Egrifta WR, for one use: less belly fat in adults with HIV and lipodystrophy. No FDA-approved ipamorelin product was found. Its phase 2 trial after bowel surgery did not show a benefit on its main or other measured outcomes. Studies do not show that either one builds muscle or slows aging.
Evidence levels: Established vs EmergingLiraglutide and semaglutide both have FDA-approved products. Victoza and Saxenda contain liraglutide. Ozempic, Rybelsus, Wegovy, and Wegovy HD contain semaglutide. Each product has its own approved uses and label. The records contain no study that compares the two directly, so this page does not rank them.
Evidence levels: Established vs EstablishedTeriparatide (Forteo) and abaloparatide (Tymlos) both have FDA-approved products for osteoporosis in defined groups at high fracture risk. Trials in postmenopausal osteoporosis found fewer spine and non-spine fractures. The records do not show that either one is better, or that either heals every new fracture faster.
Evidence levels: Established vs EstablishedNeither GHRP-6 nor ipamorelin had an FDA-approved product in the records checked on August 30 and July 23, 2026. Short human studies show growth-hormone release. They do not show fat loss, muscle gain, or faster recovery. Ipamorelin's phase 2 trial after bowel surgery did not show a benefit. WADA's 2026 rules prohibit both.
Evidence levels: Emerging vs EmergingTesamorelin's August 1, 2026 review lists two FDA-approved products, Egrifta SV and Egrifta WR. Their one use is less belly fat in adults with HIV and lipodystrophy. Tesamorelin is not approved for weight loss. CJC-1295's August 2, 2026 review found no FDA-approved product. CJC-1295's studies in healthy adults measured hormone levels. Studies do not show that either one causes general fat loss or builds muscle.
Evidence levels: Established vs EmergingNeither CJC-1295 nor sermorelin had a current FDA-approved U.S. product in reviews dated August 2 and July 23, 2026. Sermorelin was once approved as Geref, and those products are no longer sold. Studies in people show hormone changes for both. They do not show that either one builds muscle or reduces body fat.
Evidence levels: Emerging vs EmergingOpen a full record
Each record keeps its own evidence notes, source list, review date, and safety limits.
Keep this in mind
CJC-1295 and ipamorelin show why this matters. Studies found hormone changes in people, but reliable studies do not show the claimed muscle, fat-loss, or recovery benefits.
Learn how to read research